Pharming Group NV (PHAR)
11.77
+0.31
(+2.71%)
USD |
NASDAQ |
Aug 25, 16:00
11.96
+0.19
(+1.61%)
After-Hours: 19:59
Pharming Group Net Income (Quarterly) : 1.598M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 1.598M |
| March 31, 2026 | -5.232M |
| December 31, 2025 | 5.296M |
| September 30, 2025 | 7.466M |
| June 30, 2025 | 4.662M |
| March 31, 2025 | -14.90M |
| December 31, 2024 | 3.674M |
| September 30, 2024 | -1.037M |
| June 30, 2024 | -1.199M |
| March 31, 2024 | -12.42M |
| December 31, 2023 | -2.722M |
| September 30, 2023 | 3.446M |
| June 30, 2023 | 1.317M |
| March 31, 2023 | -12.26M |
| December 31, 2022 | -14.75M |
| September 30, 2022 | 9.055M |
| June 30, 2022 | 15.64M |
| March 31, 2022 | 3.452M |
| December 31, 2021 | 2.058M |
| September 30, 2021 | -0.4177M |
| June 30, 2021 | 5.822M |
| March 31, 2021 | 8.501M |
| December 31, 2020 | 8.869M |
| September 30, 2020 | 8.711M |
| June 30, 2020 | 10.70M |
| Date | Value |
|---|---|
| March 31, 2020 | 9.284M |
| December 31, 2019 | 13.44M |
| September 30, 2019 | 11.63M |
| June 30, 2019 | 7.703M |
| March 31, 2019 | 7.652M |
| December 31, 2018 | 12.68M |
| September 30, 2018 | 6.236M |
| June 30, 2018 | 3.608M |
| March 31, 2018 | 6.748M |
| December 31, 2017 | -49.74M |
| September 30, 2017 | -8.800M |
| June 30, 2017 | -26.95M |
| March 31, 2017 | -6.126M |
| December 31, 2016 | -7.648M |
| September 30, 2016 | -4.135M |
| June 30, 2016 | -3.782M |
| March 31, 2016 | -3.732M |
| December 31, 2015 | -4.442M |
| September 30, 2015 | -2.681M |
| June 30, 2015 | -2.388M |
| March 31, 2015 | -1.493M |
| December 31, 2014 | 16.37M |
| September 30, 2014 | 1.684M |
| June 30, 2014 | -5.633M |
| March 31, 2014 | -21.97M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| ProQR Therapeutics NV | -10.15M |
| NewAmsterdam Pharma Co. NV | -64.14M |
| argenx SE | -- |
| DBV Technologies SA | -- |
| ACADIA Pharmaceuticals, Inc. | 31.50M |
Net Income (Quarterly) Related Metrics
| Revenue (Quarterly) | 90.08M |
| Total Expenses (Quarterly) | 88.48M |
| EPS Diluted (Quarterly) | 0.02 |
| Enterprise Value | 801.53M |
| Gross Profit Margin (Quarterly) | 80.56% |
| Profit Margin (Quarterly) | 1.77% |
| Earnings Yield | 1.06% |
| Operating Earnings Yield | 2.58% |
| Normalized Earnings Yield | 1.893 |